49 results on '"Shaughnessy, Jr., John D."'
Search Results
2. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
3. A gene signature can predict risk of MGUS progressing to multiple myeloma
4. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
5. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
6. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines
7. A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance
8. A 5-Stage System for ASCT Multiple Myeloma
9. Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma
10. Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
11. Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma
12. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions
13. Single Nuclei Multiomics Analysis of Transcriptional and Chromatin Accessibility of Tumor Cells Uncovers Molecular Signatures and Regulatory Elements of Malignant Clonal Evolution in Multiple Myeloma
14. Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma
15. Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease
16. Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma
17. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma
18. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
19. Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use
20. Characterization of Wnt/β-catenin signalling in osteoclasts in multiple myeloma
21. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile
22. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
23. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols
24. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
25. Gene Expression Signature in MGUS and Multiple Myeloma.
26. CGO: utilizing and integrating gene expression microarray data in clinical research and data management
27. Mouse Chromosomal Location of Three Epithelial Sodium Channel Subunit Genes and an Apical Sodium Chloride Cotransporter Gene
28. Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels.
29. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
30. Maximum predictive power of the microarraybased models for clinical outcomes is limited by correlation between endpoint and gene expression profile.
31. Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone.
32. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
33. Characterization of Wnt/β-catenin signalling in osteoclasts in multiple myeloma.
34. Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma.
35. Myeloma Molecular Pathways and Cytogenetics.
36. Complete Remission Sustained 3 Years From Treatment Initiation Is a Powerful Surrogate for Extended Survival in Multiple Myeloma.
37. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
38. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
39. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway.
40. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.
41. Mrvil, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1.
42. Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression.
43. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
44. Myeloma is on the move
45. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
46. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
47. CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.
48. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.
49. Heparanase Enhances Syndecan-1 Shedding.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.